Back to User profile » Dr Javier De Castro
Paper published by Dr Javier De Castro:
Original Research
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D
ClinicoEconomics and Outcomes Research 2017, 9:31-38
Published Date: 30 December 2016